30th week of 2012 patent applcation highlights part 37 |
Patent application number | Title | Published |
20120189590 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 2012-07-26 |
20120189591 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 2012-07-26 |
20120189592 | METHODS FOR PROMOTING HEMATOPOIETIC RECONSTITUTION - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 2012-07-26 |
20120189593 | METHODS FOR PROMOTING HSC ENGRAFTMENT - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 2012-07-26 |
20120189594 | METHODS FOR PROMOTING HSC SELF-RENEWAL - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 2012-07-26 |
20120189595 | INDUCED PLURIPOTENT STEM CELLS AND METHODS OF USE - The invention relates to the field of stem cells and, specially, to the reprogramming of adult somatic cells; to obtain pluripotent cells by the transfection of specific genes. Thus, the invention provides induced pluripotent stem cells (iPS) and methods of obtaining and using them. | 2012-07-26 |
20120189596 | NUCLEAR RECEPTOR AND MUTANT THEREOF AND THE USE OF THE SAME IN THE REPROGRAMMING OF CELLS - According to the invention there is provided methods for inducing pluripotent stem cells in vitro, comprising introducing a gene or polypeptide of a nuclear receptor and one or more gene or polypeptide selected from the group consisting of Sox, Krüppel-like factor or the myc family, to cells in vitro. The present invention also provides vectors and compositions for producing the same and methods for using the induced pluripotent stem cell for treating a patient in need of a pluripotent stem cell treatment. | 2012-07-26 |
20120189597 | NUTRITIONAL COMPOSITIONS INCLUDING EXOGENOUS NUCLEOTIDES - Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including one or more exogenous nucleotides. | 2012-07-26 |
20120189598 | ORAL NUTRITIONAL SUPPLEMENT FOR CHILDREN COMPRISING PROBIOTICS - The present invention relates to the field of nutrition for children. In particular, the present invention relates to the field of oral supplements. One embodiment of the present invention relates to the field of oral supplements comprising probiotics and/or bioactive non-replicating probiotics, for example heat treated probiotics. | 2012-07-26 |
20120189599 | MEDICATION FOR ORAL ADMINISTRATION, COMPRISING AT LEAST ONE ESTROGEN AND/OR AT LEAST ONE GESTAGEN AND AT LEAST ONE PROBIOTIC BACTERIAL STRAIN - The present invention relates to a medicament for oral administration containing at least one estrogen and/or one gestagen and at least one probiotic bacterial strain, such as for example | 2012-07-26 |
20120189600 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES - The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis. | 2012-07-26 |
20120189601 | ASSISTED ENZYME REPLACEMENT THERAPY - Reagents and methods useful for the synthesis of conjugates comprising guanidinylated cyclic acetals are provided. Also provided are methods for increasing the cellular uptake of various therapeutic compounds and treatment modalities using these conjugates. | 2012-07-26 |
20120189602 | Treatment and prevention of pulmonary conditions - The invention provides compositions and methods for treating pulmonary conditions and for reducing the negative effects of pulmonary inflammation. Such compositions and methods employ protease inhibitors and a lung surfactant mixture. The compositions and methods can also include lipase inhibitors (e.g. a phospholipase inhibitors) and anti-oxidants. | 2012-07-26 |
20120189603 | STORAGE-STABLE, SYNERGISTIC MICROBICIDAL CONCENTRATES CONTAINING AN ISOTHIAZOLONE, AN AMINE AND AN OXIDIZING AGENT - A microbicidal composition in the form of a concentrate includes a) one or more isothiazolin-3-ones, b) one or more organic amines with an alkyl group having at least 8 carbon atoms and c) one or more oxidizing agents. The concentrate is storage-stable and is used for the preservation of technical and domestic products. | 2012-07-26 |
20120189604 | PURIFICATION AND ISOLATION OF RECOMBINANT OXALATE DEGRADING ENZYMES AND SPRAY-DRIED PARTICLES CONTAINING OXALATE DEGRADING ENZYMES - The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions. | 2012-07-26 |
20120189605 | MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN N-ACETYLGALACTOSAMINE-6-SULFATASE AND USES THEREOF - This invention provides compositions of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase (GALNS), and pharmaceutical compositions and formulations thereof, methods of producing and purifying GALNS, and its use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the GALNS enzyme, e.g., Mucopolysaccharidosis IVa (MPS IVa or Morquio A syndrome). | 2012-07-26 |
20120189606 | Antimicrobial Agents - The present invention relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The present invention also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said fusion protein. | 2012-07-26 |
20120189607 | METHOD OF REGULATING FERTILIZING ABILITY USING CYCLIC ADP-RIBOSE AND CD38 - The present invention relates to a pharmaceutical composition for promoting fertilization comprising cyclic ADP-ribose or its derivative, CD | 2012-07-26 |
20120189608 | NEW ENDOLYSIN OBPGPLYS - The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said polypeptide or fusion protein for the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said polypeptide or fusion protein. | 2012-07-26 |
20120189609 | IMPROVEMENT TO TRABECULECTOMY - The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of a plasmin or active derivative thereof in the form of topical eye drops alone, by anterior chamber injection alone, or by any combination of these. | 2012-07-26 |
20120189610 | TREATMENT OF PAIN - Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. | 2012-07-26 |
20120189611 | DIPEPTIDYL PEPTIDASE-4 INHIBITOR - The present invention aims to provide a DPP-4 inhibitor that is obtained by using a food as a raw material and that is suitable for oral ingestion from the viewpoints of flavor and absorbability, and a composition for the prevention and/or amelioration of diabetes which contains the DPP-4 inhibitor. The present invention provides a DPP-4 inhibitor obtained by treating an azuki bean or a kidney bean with a microorganism or a proteolytic enzyme produced by the microorganism. In particular, a preferable DPP-4 inhibitor can be obtained by hydrolyzing an azuki bean with a koji mold or a proteolytic enzyme derived from the koji mold to fragment a protein in the azuki bean. | 2012-07-26 |
20120189612 | COMPOSITIONS AND METHODS FOR TREATING CANCER WHILE PREVENTING OR REDUCING CARDIOTOXICITY AND/OR CARDIOMYOPATHY - The present invention provides methods for treating cardiotoxicity, cardiomyopathy, and/or cancer in a subject, as well as related compositions and kits, that employ a therapeutic agent, or a nucleic acid sequence encoding a therapeutic agent, selected from apolipoprotein A-1 (ApoA1), an ApoA1 mimetic, an agent that increases expression of ApoA1, or a binding agent specific for oxidized ApoA1, where the therapeutic agent is effective in preventing or reducing the level of cardiotoxicity and/or cardiomyopathy induced by the chemotherapeutic. | 2012-07-26 |
20120189613 | STIM2-MEDIATED CAPACITIVE CALCIUM ENTRY - The present invention relates to a pharmaceutical composition comprising an inhibitor of STIM2 or an inhibitor of STIM2-regulated plasma membrane calcium channel activity and optionally a pharmaceutically acceptable carrier, excipient and/or diluent. Furthermore, the present invention relates to an inhibitor of STIM2 or an inhibitor of STIM2-regulated plasma membrane calcium channel activity for the treatment and/or prevention of a neurological disorder associated with pathologically increased cytosolic calcium concentrations. Also disclosed are methods of treating and/or preventing a neurological disorder associated with pathologically increased cytosolic calcium concentrations comprising administering a pharmaceutically effective amount of an inhibitor of STIM2 or of an inhibitor of STIM2-regulated plasma membrane calcium channel activity to a subject in need thereof. The present invention further relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a neurological disorder associated with pathologically increased cytosolic calcium concentrations. | 2012-07-26 |
20120189614 | INHIBITORS OF FILOVIRUS ENTRY INTO HOST CELLS - Organic compounds showing the ability to inhibit viral glycoprotein (GP)-mediated entry of a filovirus into a host cell are disclosed. The disclosed filovirus entry inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by filovirus including the type species Marburg virus (MARV) and Ebola virus (EBOV). Preferred inhibitors of the invention provide therapeutic agents for combating the Ivory Coast, Sudan, Zaire, Bundibugyo, and Reston Ebola virus strains. | 2012-07-26 |
20120189615 | CROSS- STRUCTURE COMPRISING AMYLOID-BINDING PROTEINS AND METHODS FOR DETECTION OF THE CROSS- STRUCTURE, FOR MODULATING CROSS- STRUCTURES FIBER FORMATION AND FOR MODULATING CROSS- STRUCTURE-MEDIATED TOXICITY - The invention relates to the field of biochemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to cross-β structures and the biological role of these cross-β structures. In one embodiment, the invention discloses a method for modulating extracellular protein degradation and/or protein clearance comprising modulating cross-β(beta) structure formation (and/or cross-β structure-mediated activity) of the protein present in the circulation. | 2012-07-26 |
20120189616 | ISOSORBIDE NITRATES - The present invention relates to new 3-substituted 6-nitrooxy-hexahydrofuro[3,2-b]furane derivatives possessing a superior pharmacological activity in thrombosis and in coronary ischemia models. | 2012-07-26 |
20120189617 | ANTI-TIM-3 ANTIBODY - The present invention provides an anti-human TIM-3 antibody which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure thereof and exhibits higher effector activity such as an antibody-dependent cellular cytotoxicity (ADCC activity) for diseases relating to a human TIM-3 expressing cell. The present invention provides a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient. In addition, the present invention provides an anti-human TIM-3 antibody having high ADCC activity by screening an anti-human TIM-3 antibody which competes with the monoclonal antibody or the antibody fragment thereof. | 2012-07-26 |
20120189618 | SUPERIOR EFFICACY OF CD37 ANTIBODIES IN CLL BLOOD SAMPLES - The present invention describes CD37 antibodies, especially A2 and B2, for the treatment of patients with CLL, especially of patients belonging to a “high risk” or “ultra-high risk” group of patients. Those patients are either patients who are refractory to fludarabine treatment or patients who carry a genetic marker which is indicative for poor prognosis or increased risk of treatment failure, e.g. patients with TP53 dysfunction or deletion of chromosome 17p13, or patients after failure to previous anti-CD20 treatment. The ability of A2 and B2 to deplete CLL cells is high both in patient samples derived from patients with normal risk and with increased risk (“high risk” patients) and clearly superior to that of rituximab and alemtuzumab. | 2012-07-26 |
20120189619 | METHODS FOR TREATING A SPINAL DISORDER OR OSTEOARTHRITIS USING DOMINANT NEGATIVE TISSUE NECROSIS FACTOR - Effective methods of treating a spinal disorder or osteoarthritis associated with a proinflammatory agent in a patient in need of such treatment, the method comprising administering an effective amount of DN-TNF (e.g., XPro®-1595) to a target tissue site at or near the spine or osteoarthritic joint to reduce pain and/or inflammation. | 2012-07-26 |
20120189620 | METHODS FOR TREATING NON-FUNCTIONING PITUITARY ADENOMA - The disclosure is directed to methods for treating non-functioning pituitary adenomas with alpha-folate receptor (“FR-α”) and compositions. In some embodiments, the disclosure is directed to a method for treating a pituitary adenoma that includes administering farletuzumab to a subject diagnosed with a non-functioning pituitary adenoma. | 2012-07-26 |
20120189621 | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists - This invention relates generally to compositions that contain multiple modulating agents, e.g., multiple modulating agents that target CD3 on T cells and neutralize one or more biological activities of interleukin-6 (IL-6), such as CD3 modulators including anti-CD3 antibodies and anti-IL-6 antagonists including anti-IL-6 antibodies, anti-IL-6R antagonists including anti-IL-6R antibodies, and/or anti-IL-6/IL-6R complex antagonists including anti-IL-6/IL-6R binding antibodies, and methods of using these compositions in the treatment, amelioration and/or prevention of relapse of an autoimmune disease. | 2012-07-26 |
20120189622 | ANTI-CD38 HUMAN ANTIBODIES AND USES THEREOF - The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore. | 2012-07-26 |
20120189623 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS - The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds: | 2012-07-26 |
20120189624 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS - Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease. | 2012-07-26 |
20120189625 | Compositions and Methods for Treating Hematological Cancers Targeting the SIRPA CD47 Interaction - The invention relates to modulating the SIRPα-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPα polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia. | 2012-07-26 |
20120189626 | TREATMENT OF COMPLEMENT-ASSOCIATED DISORDERS - The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders. | 2012-07-26 |
20120189627 | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses - The invention relates to semi-synthetic biologic molecules which are conjugates of GLP-1 peptides and human multimeric proteins or protein fragments, such as an antibody Fc joined by a non-peptidyl bond. The constructs demonstrate biological activity and are useful making therapeutic compositions and therapeutic formulations for use in treating diseases characterized by lack of glycemic control. | 2012-07-26 |
20120189628 | ANTI-IL-TIF ANTIBODIES AND METHODS OF USING IN INFLAMMATION - The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed. | 2012-07-26 |
20120189629 | ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ORAL MUCOSITIS - The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis. | 2012-07-26 |
20120189630 | BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES - We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These are promising therapeutic agents. | 2012-07-26 |
20120189631 | PHARMACEUTICAL COMPOSITION FOR TREATING ISCHEMIC EVENTS - Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed. | 2012-07-26 |
20120189632 | METHOD FOR EXTENDING PREGNANCY IN PATIENTS EXHIBITING AT LEAST ONE SYMPTOM OF PREECLAMPSIA AND ECLAMPSIA - A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity. | 2012-07-26 |
20120189633 | ANTI-KIT ANTIBODIES AND USES THEREOF - Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein. | 2012-07-26 |
20120189634 | TACI AS AN ANTI-TUMOR AGENT - A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the TACI reagent. | 2012-07-26 |
20120189635 | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) - The present invention provides methods for treating or preventing malaria by administering to a patient in need thereof a pharmaceutical composition comprising an antibody that specifically binds human angiopoietin-2 (Ang-2). | 2012-07-26 |
20120189636 | HUMAN SERUM AMYLOID-A3 ANTIBODY AND USE THEREOF - The objective of the invention is to prepare an antibody to human SAA3 whose in vivo presence has not yet been identified in humans, thereby revealing the presence of in vivo human SAA3 and the relationship between human SAA3 and disease, and also to provide a method for treating such disease. More specifically our objective is to create an antibody to counter human serum amyloid-A3 and a kit for detecting and measuring human serum amyloid-A3 employing the aforementioned antibody, as well as a therapeutic cancer agent that can be utilized in methods to treat and diagnose cancer. | 2012-07-26 |
20120189637 | METHODS FOR TREATING PSORIASIS - The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 2012-07-26 |
20120189638 | METHOD OF TREATING NEURODEGENERATIVE DISEASE - The invention is directed to a method of treating a patient suffering from Alzheimer's disease comprising administering to said patient an agent that reduces the activity of the IGF-1 signaling pathway. | 2012-07-26 |
20120189639 | ANTI-GITR ANTIBODIES - Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders. | 2012-07-26 |
20120189640 | Methods and Compositions Related to Soluble Monoclonal Variable Lymphocyte Receptors of Defined Antigen Specificity - Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed. | 2012-07-26 |
20120189641 | COMBINATION ANTI-CANCER THERAPY - The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of either an anti-IGF-1R antibody or an IGF binding protein (e.g. IGFBP3), and a small molecule IGF-1R kinase inhibitor (e.g. OSI-906). The present invention also provides a pharmaceutical composition comprising either an anti-IGF-1R antibody or an IGF binding protein (e.g. IGFBP3), and a small molecule IGF-1R kinase inhibitor (e.g. OSI-906), with a pharmaceutically acceptable carrier. | 2012-07-26 |
20120189642 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE - In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (a) and include tautomers, solvates, prodrugs, esters, and deuterates thereof, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R | 2012-07-26 |
20120189643 | Toll Like Receptor 3 Antagonists, Methods and Uses - Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 2012-07-26 |
20120189644 | ANTI-MESOTHELIN IMMUNOCONJUGATES AND USES THEREFOR - The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors. The immunoconjugates comprise antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. | 2012-07-26 |
20120189645 | Compositions and methods to treat and control tumors - The present application is directed to non-coding RNA motifs that are used in conjunction with an antigen or without an antigen to induce, enhance or modulate an immune response that compromises a B cell and a T cell component. | 2012-07-26 |
20120189646 | NOVEL COMPOUNDS - Disclosed herein are a compound of formula (I) and pharmaceutically acceptable salts thereof, processes for preparing the same, pharmaceutical compositions containing the same, and methods of using the same. | 2012-07-26 |
20120189647 | POLYPEPTIDE SEQUENCE INVOLVED IN THE MODULATION OF THE IMMUNOSUPPRESIVE EFFECT OF VIRAL PROTEINS - Mutated viral ENV proteins having mutations in the immunosuppressive domain (ISU) of the transmembrane subunit (TM) have decreased immunosuppressive activity with respect to the wild-type ENV protein. Pharmaceutical compositions that include the protein and nucleic acids coding for the protein are also disclosed. | 2012-07-26 |
20120189648 | INFECTIOUS HEPATITIS C VIRUSES OF GENOTYPE 3A AND 4A AND USES THEREOF - The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses. | 2012-07-26 |
20120189649 | Vaccines and Compositions Against Streptococcus Pneumoniae - is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in | 2012-07-26 |
20120189650 | IMMUNOGENIC COMPOSITION COMPRISING VARIANTS OF STAPHYLOCOCCAL CLUMPING FACTOR A - The present invention relates to ClfA polypeptides wherein amino acid Y474 or an amino acid adjacent to Y474 is mutated such that fibrinogen binding activity is decreased compared to an equivalent ClfA polypeptide without mutation of Y474 or an amino acid adjacent to Y474 as well as immunogenic compositions, vaccines, processes and uses of such mutated ClfA polypeptides. | 2012-07-26 |
20120189651 | ACTIVE AGENT COMPLEX AND FORMULATION COMPRISING THE ACTIVE AGENT COMPLEX - The present invention relates to an active agent complex of extracts of | 2012-07-26 |
20120189652 | FREE RADICAL-INDUCED INTRACELLULAR DNA DAMAGE REDUCING REAGENT, MEDICAMENT OR HEALTH FOOD AND SKIN CARE PRODUCT OR COSMETIC, AND METHODS FOR PREPARING THE SAME - The invention provides a free radical-induced intracellular DNA damage reducing reagent, including: an effective amount of a | 2012-07-26 |
20120189653 | FOOD/BEVERAGE AND PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION FOR IMPROVEMENT IN ACIDIC URINE EACH COMPRISING FUCOIDAN AS ACTIVE INGREDIENT - The present invention provides a food/drink or pharmaceutical composition for oral administration for improving an acidic urine, comprising fucoidan or a fucoidan-containing material as an active ingredient, characterized in that a urinal pH is persistently increased; use of fucoidan or a fucoidan-containing material for production of the food/drink or the pharmaceutical composition for oral administration; and a method for improving an acidic urine by persistently increasing a urinal pH of a patient, which comprises orally administering fucoidan or a fucoidan-containing material to a patient. | 2012-07-26 |
20120189654 | VACCINE - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 2012-07-26 |
20120189655 | Attenuated Live Vaccine for Prevention of Porcine Reproductive and Respiratory Syndrome - The present disclosure provides an attenuated live vaccine strain and the formulations thereof, for preventing pigs from infection of porcine reproductive and respiratory syndrome (PRRS). The preparation methods for the vaccines and the formulations are also provided. The attenuated live vaccine strain provided herein offers significant immunological protection to pigs against PRRS. The vaccine formulations of the present disclosure also have advantages in long shelf lives as well as good stability during storage. | 2012-07-26 |
20120189656 | REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS - Expression of a transgene is driven in a host cell using a pol I promoter which is not endogenous to an organism from the same taxonomic order from which the host cell is derived. | 2012-07-26 |
20120189657 | MICROBIAL VACCINE AND VACCINE VECTOR - The present invention includes cold-adapted, acid-fast bacterium for use as a vaccine and a vaccine vector. In preferred embodiments, the cold-adapted, acid-fast bacterium is a | 2012-07-26 |
20120189658 | Chimeric Influenza Virus-Like Particles Comprising Hemagglutinin - A method for synthesizing chimeric influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of chimeric influenza HA in a plant or a portion of a plant. The invention is also directed towards a VLP comprising chimeric influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding chimeric influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines. | 2012-07-26 |
20120189659 | ATTENUATED PESTIVIRUSES - This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein E | 2012-07-26 |
20120189660 | Composition for Preventing or Treating Liver Diseases, Containing Plant Stem Cell Lines Derived from the Cambium of Panax Ginseng Including Mountain Ginseng or Ginseng as Active Ingredient - The present invention relates to a composition for preventing or treating liver diseases, which contains, as an active ingredient, any one or more of a homogeneous cell line derived from the cambium of | 2012-07-26 |
20120189661 | VACCINES COMPRISING HEAT-SENSITIVE TRANSGENES - The present disclosure provides temperature sensitive essential nucleic acid molecules from a psychrophilic bacterium, proteins encoded by the nucleic acid molecules, as well as recombinant cells into which have been introduced such nucleic acid molecules. The disclosed recombinant cells containing one or more essential nucleic acid molecules from a psychrophilic bacterium are thereby made temperature sensitive, and can be administered to a mammal to induce an immune response in the mammal. | 2012-07-26 |
20120189662 | Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of M. bovis BCG and M. microti - The present invention relates to a strain of | 2012-07-26 |
20120189663 | METHOD OF PRODUCING A MEDICAL COMPOSITION - The present invention aims to produce a safe and reliable medical composition, which efficiently boosts nonspecific immunity of antigen-presenting cells and thereby promotes an antitumor activity. To produce the medical composition, antigen-presenting cells such as dendritic cells are exposed to an activating reagent containing baculoviruses. Then, the antigen-presenting cells are separated from the activating reagent. The antigen-presenting cells are optionally cultured after the separation. Furthermore, an absence of the baculoviruses in the composition are optionally checked. The medical composition produced by the present invention is expected to have an outstanding therapeutic effect. | 2012-07-26 |
20120189664 | CANCER STEM CELL ANTIGEN VACCINES AND METHODS - Method of stimulating an immune response (e.g., to treat cancer) include administering to a patient a composition including dendritic cells that present cancer stem cell antigens. Compositions including cancer stem cell antigens are also provided herein. | 2012-07-26 |
20120189665 | Cosmetic Compositions Comprising Cyanodiphenylacrylates And Film Forming Polmers - A composition comprising at least one α-cyanodiphenylacrylate and at least one organosiloxane-based film forming polymer. | 2012-07-26 |
20120189666 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT - This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent. | 2012-07-26 |
20120189667 | METHOD FOR REPAIRING OR REPLACING DAMAGED TISSUE - A method for repairing or replacing damaged tissue, or for providing post-surgical augmentation, comprising administering a pliable biocompatible material and a physiologically acceptable suspending agent to a patient is disclosed. Copolymers of unsubstituted acrylate and substituted acrylate are disclosed as pliable biocompatible materials. | 2012-07-26 |
20120189668 | HYDROGEL BIOSCAFFOLD AND COATING FOR BONE AND TOOTH REPAIR - Hydrogel compositions that include an albumin/N-acetyl cysteine solution and an aqueous suspension of calcium salts or mixture of calcium and magnesium salts are described. Also described are methods of producing and using the hydrogel compositions as a support scaffold for mineralizing connective tissue replacement and repair. | 2012-07-26 |
20120189669 | Solid Forms for Tissue Repair - This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof. | 2012-07-26 |
20120189670 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME - Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein. | 2012-07-26 |
20120189671 | Absorbable Implants and Methods for their use in Hemostasis - The invention provides body absorable, mechanically hemostatic putty compositions comprising carboxymethyl cellulose and one or more of polyhydroxy compounds, fatty acids, and esters thereof for use in controlling the bleeding of bone. | 2012-07-26 |
20120189672 | USE OF AEROSOLIZED CYCLOSPORINE FOR PREVENTION AND TREATMENT OF PULMONARY DISEASE - The present invention relates to methods and compositions for prevention of graft rejection in lung transplant recipients and for treatment of subjects with pulmonary disorders. Specifically, the methods and compositions of the invention provide a means for inhibiting immune response mediated inflammatory processes in the lungs. The method of the invention comprises the administration of aerosolized cyclosporine for prevention of acute and/or chronic refractory rejection in lung transplant patients. The invention further provides for the use of aerosolized cyclosporine to treat subjects having immunologically mediated inflammatory pulmonary disorders including, but not limited to, asthma, cystic fibrosis, idiopathic pulmonary fibrosis, chronic bronchitis and allergic rhinitis. The present invention, by enabling a method for the use of aerosolized cyclosporine for inhibiting pulmonary inflammation leading to prevention of graft rejection and treatment of pulmonary disorders, provides a safer and less toxic treatment than those methods that utilize systemic administration of cyclosporine. | 2012-07-26 |
20120189673 | POLYPEPTIDES AND USES THEREOF - The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOs: 1 to 11, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof which exhibit an anti-inflammatory and/or anti-coagulant activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation. | 2012-07-26 |
20120189674 | Compositions for topical delivery of the pharmacologically active compounds - Novel compositions for topical drug delivery of the pharmaceutically active compounds which allow active compounds to pass through the stratum corneum, epidermis and deliver to the deeper layers of the skin, dermis, are developed. The active compounds are encapsulated into the phospholipid spheres or bilayers. The phospholipid emulsion technology utilized in the skincare products provides a vastly superior method of active ingredient delivery. This method allows pharmacologically active compounds to penetrate through outer layers of the skin to reach the deep layers. As a result, the products are highly effective, cosmetically elegant and gentle on the skin. | 2012-07-26 |
20120189675 | Skin External Preparations - To provide skin external preparations which are stable and are superior in a skin-tension feeling effect or skin-elasticity feeling effect after application therewith to the skin. Also to provide skin external preparations which are excellent in adhesiveness to the skin and have a non-sticky feeling, in addition to the above described stability and the skin-tension feeling effect. A skin external preparation comprising a finely dispersed wax composition in which the wax is finely dispersed in a solid or semisolid form in an aqueous dispersion medium, which preparation is characterized in that the above finely dispersed wax composition contains a wax being solid or semisolid at ordinary temperature, a nonionic surfactant, an aqueous dispersion medium, and an ionic water-soluble thickener, optionally further contains silicone oil and/or fluorinated oil which is liquid at ordinary temperature, and the mass ratio of the nonionic surfactant to the wax being 1.0 or more, the particle size of the finely dispersed wax is 500 nm or less, and it substantially contains no ionic surfactants therein. | 2012-07-26 |
20120189676 | Cosmetic Compositions Comprising Cyanodiphenylacrylates - A composition comprising at least one α-cyanodiphenylacrylate and at least oxyalkylenated organosiloxane emulsifier, and a method for stabilizing a composition by formulating with at least one α-cyanodiphenylacrylate and at least one oxyalkylenated organosiloxane emulsifier. | 2012-07-26 |
20120189677 | FORMULATIONS - A formulation comprising botulinum toxin (BT), lipid and surfactant, characterised in that the lipid and surfactant are in the form of macromolecular assemblies of less than 100 nm in diameter. The surfactant may have an HLB number of less than 20. Cosmetic and pharmaceutical formulations and corresponding uses are contemplated and included, as are methods of preparation, | 2012-07-26 |
20120189678 | Liposome and Personal Care Composition Comprising Thereof - A liposome comprising a phospholipid, a hydrophobic active comprising a carboxylate group, and a component selected from a group consisting of: a hydrophilic adjuvant comprising a positively charged group, a complex of said hydrophobic active with said hydrophilic adjuvant, and combinations thereof. An aqueous liposome dispersion comprising the liposome, and a personal care composition comprising the liposome. A process of preparing the liposome, comprising the steps of: forming a premix by dissolving a phospholipid, a hydrophobic active comprising a carboxylate group in an organic solvent; evaporating off said organic solvent from the premix to form a phospholipid film; and hydrating said lipid film with a hydration medium comprising a hydrophilic adjuvant comprising a positively charged group and homogenize the medium to form an aqueous liposome dispersion. | 2012-07-26 |
20120189679 | METHOD FOR COATING POWDERS - The invention concerns a method for coating powdery solid active substances which includes the following steps: a) providing ( | 2012-07-26 |
20120189680 | TOOTH WHITENING STRIPS - A tooth whitening product is provided. The tooth whitening product includes film formed from a water hydratable polymer and a plasticizer. The film has a first side and a second side and a tooth whitening agent applied as coating to one side of the film. | 2012-07-26 |
20120189681 | PHOTOCATALYTIC COATING FOR THE CONTROLLED RELEASE OF VOLATILE AGENTS - A layered heterostructured coating has functional characteristics that enable the controlled release of volatile agents. The coating has photocatalytic properties, since it uses titanium dioxide, its derivatives or materials with similar photocatalytic properties ( | 2012-07-26 |
20120189682 | INHIBITION OF BIOFILM ORGANISMS - The present invention relates to a product comprising at least two antibiofilm agents wherein at least one of the antibiofilm agents is an antimicrobial peptide. The second antibiofilm agent is generally a dispersant or an anti-adhesive agent. There is also provided the use of the product in the treatment of a microbial infection. | 2012-07-26 |
20120189683 | COMPOSITE OF AMORPHOUS CALCIUM PHOSPHATE/CALCIUM SULFATE HEMIHYDRATE (CSH/ACP) FOR BONE IMPLANTATION AND PROCESS FOR PRODUCING THE SAME - The invention provides a composite of α-calcium sulfate (CS) hemihydrate/amorphous calcium phosphate (α-CSH/ACP), comprising α-CSH and ACP at a weight ratio of about 10:90 to about 90:10. Particularly, the composite of the invention has a resorption period of 3-6 months. The invention also provides a one-pot process for producing α-CSH/ACP composite of the invention. The one-pot process of the invention can produce α-CSH and ACP in a single process and easily obtain α-CSH/ACP composite. | 2012-07-26 |
20120189684 | Skincare Compositions - This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions, wherein the compositions comprise salicylic acid or a salt thereof in combination with at 2 actives selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; bisabolol; cetylhydroxyproline palmitamide; allantoin; niacinamide; and epilobium angustifolium extract. | 2012-07-26 |
20120189685 | WOUND DRESSING COMPRISING AN ANTI-INFLAMMATORY PAIN-KILLING AGENT AND A COMPLEX OF SILVER ION AND A TRANSITIONAL ELEMENT OF GROUP IV OF THE PERIODIC SYSTEM OF ELEMENTS - A wound dressing comprising one or more absorbent elements capable of absorbing wound exudates, a non-steroid anti-inflammatory pain-killing agent and a complex of silver ion and a transitional element of group IV of the periodic system of elements. | 2012-07-26 |
20120189686 | TRANSDERMAL LEVONORGESTREL DEVICE AND DELIVERY - Described are transdermal drug delivery systems for the transdermal administration of levonorgestrel, comprising a polymer matrix and levonorgestrel acetate. Methods of making and using such systems also are described. | 2012-07-26 |
20120189687 | Compositions and Methods for Topical Application of Growth Factors and Cytokines - A composition for therapeutically enhancing skin health by allowing growth factors derived from stem cells or fibroblasts to penetrate within the epidermis to increase the proliferation, growth and differentiation of skin cells. The composition includes at least one and preferably plural growth factors that are encapsulated within liposomes. Cytokines may also be encapsulated as well. The liposomally encapsulated growth factors and/or cytokines are able to penetrate into the basal skin cell layer to attach to the skin cells or penetrate through the follicles to reach the dermis. | 2012-07-26 |
20120189688 | CARRIER COMPONENT AND FABRICATION METHOD THEREOF - The present invention provides a carrier component. The carrier component includes a carrier core body including a dispersive object and a dualistic self-assembly material for encapsulating the dispersive object, wherein the dualistic self-assembly material has an electric charge; and a first shell layer having an electric charge opposite to the electric charge of the dualistic self-assembly material, and coating the carrier core body, and thus avoids inactivation of a medicine, eliminates medicine leakage and reduces medicine releasing. The present invention further provides a method for forming a carrier component. | 2012-07-26 |
20120189689 | ACOUSTICALLY SENSITIVE DRUG DELIVERY PARTICLES COMPRISING NON-LAMELLAR FORMING PHOSPHATIDYLCHOLINE - Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy. | 2012-07-26 |